Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Moderate Buy" by Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fourteen ratings firms that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $40.33.

KROS has been the subject of a number of research reports. Guggenheim reissued a "neutral" rating on shares of Keros Therapeutics in a research report on Friday, January 17th. HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Scotiabank dropped their price objective on Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a report on Thursday, January 16th. Oppenheimer reduced their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a research note on Thursday, January 16th. Finally, Cantor Fitzgerald lowered shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Tuesday, January 21st.

Insiders Place Their Bets

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the company's stock in a transaction on Wednesday, April 9th. The shares were bought at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the transaction, the insider now directly owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This represents a 27.01 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 22.90% of the company's stock.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC raised its stake in Keros Therapeutics by 7,690.3% during the 1st quarter. GAMMA Investing LLC now owns 2,415 shares of the company's stock valued at $237,000 after purchasing an additional 2,384 shares during the last quarter. FNY Investment Advisers LLC bought a new position in shares of Keros Therapeutics during the 1st quarter worth about $25,000. AlphaQuest LLC raised its position in shares of Keros Therapeutics by 469.0% during the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock valued at $57,000 after buying an additional 2,964 shares during the last quarter. Virtus ETF Advisers LLC lifted its stake in shares of Keros Therapeutics by 107.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock valued at $61,000 after buying an additional 1,998 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new stake in Keros Therapeutics during the fourth quarter worth about $90,000. Institutional investors and hedge funds own 71.56% of the company's stock.

Keros Therapeutics Stock Down 1.5 %

Shares of KROS traded down $0.21 during trading hours on Tuesday, reaching $14.21. The company's stock had a trading volume of 1,003,205 shares, compared to its average volume of 797,085. The company has a 50 day moving average of $11.49 and a two-hundred day moving average of $28.18. The firm has a market cap of $576.39 million, a price-to-earnings ratio of -2.73 and a beta of 1.39. Keros Therapeutics has a 1-year low of $9.12 and a 1-year high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.36) by $0.22. The firm had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. As a group, analysts forecast that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.